

S/N TBD**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Drivas, D.)	Examiner:	TBD
Serial No.:	TBD)	Group Art Unit:	TBD
	(National Stage of PCT/US)		
	04/008901))		
Filed:)	Attorney Docket:	MP-02
Title:	Methods and Compositions for)		
	Treating and Preventing)		
	Inflammatory Conditions)		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. §§ 1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), no fee or statement is required with this Information Disclosure Statement. If a fee is required, please charge the same to Deposit Account 50-3464.

10/550866

JC09 Rec'd PCT/PTO 23 SEP 2005

Page 2

Serial No.: TBD

The Examiner is invited to contact the Applicant's representative at the below-listed telephone number if there are any questions.

Respectfully submitted,

Dated: September 23, 2005


Thomas Hoxie
Reg. No. 32,993

HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, NJ 07041
(973) 467-2126

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being mailed via Express Mail, label number ED757366113US, in a box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23rd day of September, 2005.

Thomas Hoxie
Name


Signature

10/550866

PTO/SB/08A(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	TBD JC09 Rec'd PCT/PTO 23 SEP 2009
		Filing Date	
		First Named Inventor	Dimitrios T. Drivas
		Group Art Unit	
		Examiner Name	
Sheet 1 of 2		Attorney Docket No: MP-02	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,403,782 B1	6/2002	Luster et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	03-24-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

10/550866

PTO/SB/08A(08-03)

Approved for use through 07/31/2008, OMB 0651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	TBD JC09 Rec'd PCT/PTO 23 SEP 2005
		Filing Date	
		First Named Inventor	Dimitrios T. Drivas
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2		Attorney Docket No: MP-02	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs, Biochemical and Biophysical Research Communications</i> , November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation, J. Exp. Med.</i> , March 1994, pages 881-887, Vol. 179	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia, Nature Medicine</i> , April 1996, pages 449-456, Vol. 2, No. 4.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

• EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached